Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $16.67 Average Target Price from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been assigned a consensus rating of “Hold” from the four research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $16.67.

Several equities analysts have recently weighed in on ATRA shares. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Mizuho raised Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price target for the company from $25.00 to $18.00 in a report on Friday, August 16th. Finally, Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, November 13th.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of institutional investors have recently bought and sold shares of ATRA. BNP Paribas Financial Markets raised its holdings in Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the period. Acadian Asset Management LLC raised its holdings in Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares during the period. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics in the 1st quarter worth $29,000. Price T Rowe Associates Inc. MD raised its holdings in Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after purchasing an additional 4,903,159 shares during the period. Finally, Redmile Group LLC increased its stake in Atara Biotherapeutics by 1.7% in the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after buying an additional 156,863 shares in the last quarter. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Trading Up 8.1 %

ATRA stock opened at $11.47 on Monday. The stock has a market capitalization of $66.07 million, a PE ratio of -0.44 and a beta of 0.50. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50. The stock’s 50 day simple moving average is $9.23 and its 200 day simple moving average is $10.02.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the company posted ($16.50) earnings per share. On average, research analysts predict that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.